Antibiotics serve a useful therapeutic purpose for the treatment and control of pathogens. The medications are used to either inhibit or prevent bacterial infections referred as bactericidal and bacteriostatic antibiotics, respectively. Various types of antibiotics such as penicillin, cephalosporin, carbapenem, and monobactam are available in pharmacies and hospitals that are used to treat infectious diseases. However, the antibiotic resistance is a global problem and it is considered as a threat, owing to its effect on morbidity and mortality. The treatment with the help of oral antibiotics has the potential to reduce prolonged hospital stay, treatment cost, and further complications. Oral drug delivery continues to rise in popularity as key players are focused on extending R&D efforts, thereby improving patient convenience.ย
List of Key Players
The key players operating in the global oral antibiotics market include Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/6905
The economies across the world are suffering from the impact of COVID-19 and many industries are experiencing losses. However, pharmaceutical companies have a center stage in the COVID-19 fight and are responding to rapid challenges. Whereas, the Covid-19 pandemic has impacted moderately on oral antibiotics market, as the coronavirus damages cells so badly that it becomes easier for certain bacteria to cause secondary infections. For instance, bacterial pneumonia in influenza patients, which can be treated with antibiotics. Hence, the macrolide antibiotics such as azithromycin, erythromycin, clarithromycin, and spiramycin are prescribing for the treatment of secondary infections.
The oral antibiotics market is expected to exhibit significant growth during the forecast period, owing to factors such as increased consumption in low and middle-income countries (LMICs) and rise in prevalence of infectious diseases along with imbalance of supply-demand of antibiotics. In addition, rise in R&D efforts undertaken by key players operating in the market for development of advanced oral antibiotics to treat bacterial infections and carry out a large number of clinical trials further supplements the market growth. In addition, use of novel approaches for development of new oral antibiotics for treating bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and the time taken for regulatory approvals are projected to hamper the market growth. Furthermore, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant opportunities for the market players.
The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications such as acute respiratory distress syndrome, usually as a result of pneumonia. In the pandemic situation antibiotics are considered to have an important part in the disease treatment. COVID-19 has led to increase in the bacterial infections, as antibiotics are prescribed to prevent secondary infections following an antiviral immune response. Various antibiotics therapies have also been commonly used to support COVID19 treatments globally, which drives the use of oral antibiotics as the first line of treatment.
For Purchase inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/6905
Key Findings Of The Study
- By class, the beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018.
- On the basis of spectrum of activity, the broad-spectrum segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 3.3% from 2019 to 2027.
- Depending on application, the community-respiratory tract infections segment is expected to exhibit the highest CAGR during the forecast period.
- By drug origin, the semisynthetic segment was the major revenue contributor in 2018.
- By drug type, the branded segment accounted for largest revenue in 2018, and is expected to be dominant during the forecast period.
- LAMEA is estimated to grow at a CAGR of 3.3% during the forecast period.
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.